In this interview with Hearing Health Matters, Celia and Peter recount their successful strategic collaboration, marking its fifth anniversary, and their recent award for their innovative preclinical auditory services in the third annual Hearing Technology Innovator Awards.
Celia and Peter discuss how CILcare-CBSET built the partnership and fostered innovation to accelerate the development of auditory therapies. They also shed light on the connection between hearing loss and other diseases, sharing their vision of the future for hearing loss treatment.
We warmly thank Brian Taylor and his team for setting up this interview which emphasizes exciting research perspectives in the field of hearing disorders.
About the panel:
Celia BELLINE, CILcare’s CEO: Celia has over 20 years’ experience in the pharmaceutical industry. She worked as the global head of clinical trial logistics and supply chains in Sanofi R&D, was a permanent member of clinical strategic committees, and the Director of projects dealing with major chronic diseases associated with aging, where she developed her interest and expertise in hearing disorders. She trained at ESSEC and London Business Schools, in addition to holding several master’s degrees in project management, industrial strategy and health environment. In 2014, Celia along with Drs. Sylvie Pucheu & Marie-Pierre Pasdelou, founded CILcare, a Smart R&D platform dedicated to the acceleration and development of novel therapies to prevent and treat ear disorders, with offices in Boston, MA, France, and Denmark.
Peter MARKHAM, CBSET’s CEO: Peter has 30 years of management and regulatory experience in GLP contract research. Prior to cofounding CBSET in 2006, he was general manager of the Worcester/Southbridge division of Charles River Laboratories, a multi-disciplinary pre-clinical business unit which serviced the Toxicology, Pharmacology, Surgery, Metabolism, Pharmacokinetics, and Bioanalytical Chemistry markets. Previously, he served as a senior executive in leadership roles at various research companies including Genzyme Transgenics, Primedica, BioDevelopment Laboratories, and Arthur D. Little. He has broad expertise in both drug and device development with over two decades of scientific leadership in drug metabolism, pharmacokinetics, bioanalytical chemistry, and the application of these scientific disciplines to the development of combination products. Mr. Markham holds a BS and MS in Bioanalytical Chemistry from University of Massachusetts.
Brian Taylor, AuD: Brian is the senior director of audiology for Signia. He is also the editor of Audiology Practices, a quarterly journal of the Academy of Doctors of Audiology, editor-at-large for Hearing Health and Technology Matters and adjunct instructor at the University of Wisconsin.
HHTM’s mission is to bridge the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Our contributors and readers are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them.
